Physician profile
Christopher Topel
NPI 1578857199
$6,617.28
in general payments reported to CMS, 2019-2025
21 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $435 · 2021: $893 · 2022: $1,211 · 2023: $1,325 · 2024: $704 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182 · Education: $99.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.79 |
| Education | $99.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $932.18 | 2019-2024 | Austedo Xr |
| Amgen INC. | $749.44 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $591.73 | 2022-2023 | Ongentys, Ingrezza |
| Medtronic, INC. | $520.40 | 2021-2024 | Linq II |
| Abbvie INC. | $498.91 | 2022-2025 | Avycaz |
| Astrazeneca Pharmaceuticals LP | $468.33 | 2022-2023 | Andexxa |
| Chiesi USA, INC. | $416.93 | 2019-2025 | Cleviprex |
| Lilly USA, LLC | $299.40 | 2019 | |
| Penumbra, INC. | $277.91 | 2019-2021 | |
| Argenx US, INC. | $274.36 | 2022-2024 | Vyvgart |
| Medtronic Vascular, INC. | $236.14 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $221.56 | 2020-2021 | |
| Mdd US Operations, LLC | $203.80 | 2019-2023 | Apokyn |
| Stryker Corporation | $162.05 | 2022 | |
| Abbott Laboratories | $125.13 | 2023 | Amplatzer Amulet |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $125.00 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2024 | Opsumit, Uptravi |
| Piramal Critical Care | $124.98 | 2022 | |
| Alcresta Therapeutics, INC. | $121.83 | 2024 | Relizorb |
| Shire North American Group INC | $109.04 | 2019 | |
| Ceribell, INC. | $33.16 | 2025 | Pocket Eeg Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Topel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.